Related Experiment Video
Updated: Jan 8, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Complementary strategies in pancreatic cancer precision medicine: therapeutic prediction and immune modulation
Wonmin Lee1,2, Hyun-Myung Woo3, Ja Hyang Cho4
1Translational-Transdisciplinary Research Center, Medical Science Research Institute, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Background:
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal with five-year survival below 10%, primarily due to late diagnosis, treatment resistance, and immunosuppressive microenvironment.
Methods:
This review examines recent advances in PDAC precision medicine by analyzing organoid-based drug screening platforms, mRNA immunotherapy developments, and integrated diagnostic technologies.
Results:
Patient-derived organoids demonstrate strong predictive value for clinical outcomes, with drug sensitivity profiles correlating with patient responses (concordance >80%). Personalized mRNA neoantigen vaccines induce robust T-cell responses, with vaccine responders showing significantly prolonged recurrence-free survival (median not reached vs. 13.4 months). KRAS-targeted therapies achieve 10-15% response rates in G12C-mutant PDAC. Integration of spatial transcriptomics and liquid biopsy enables real-time molecular monitoring.
Conclusions:
The development of patient-derived organoids for drug sensitivity testing, personalized mRNA vaccines for immune activation, and precision diagnostic and therapeutic technologies represents complementary advances in PDAC. While each approach has demonstrated independent clinical value, their integration remains an important future direction that may provide a comprehensive framework for improving outcomes in PDAC.
Insights
Precision medicine advances, including organoid drug screening and mRNA vaccines, offer new hope for pancreatic cancer (PDAC). Integrating these technologies may significantly improve patient outcomes and survival rates.
Area of Science:
- Oncology
- Genomics
- Immunotherapy
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a dismal five-year survival rate below 10%.
- Late diagnosis, treatment resistance, and an immunosuppressive tumor microenvironment contribute to PDAC's lethality.
Purpose of the Study:
- To review recent advancements in precision medicine for pancreatic ductal adenocarcinoma.
- To analyze organoid-based drug screening, mRNA immunotherapy, and integrated diagnostic technologies.
Main Methods:
- Review of organoid-based drug screening platforms.
- Analysis of mRNA immunotherapy developments.
- Examination of integrated diagnostic technologies for PDAC.
Main Results:
- Patient-derived organoids show >80% concordance in predicting drug sensitivity.
- Personalized mRNA neoantigen vaccines enhance T-cell responses and prolong recurrence-free survival.
- KRAS-targeted therapies show 10-15% response rates in G12C-mutant PDAC; integrated diagnostics enable real-time monitoring.
Conclusions:
- Patient-derived organoids, mRNA vaccines, and precision diagnostics are complementary advances for PDAC.
- Each approach shows independent clinical value.
- Integration of these technologies is a crucial future direction for improving PDAC outcomes.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...